Australia's most trusted
source of pharma news
Thursday, 02 May 2024
Posted 18 April 2024 AM
Firebrick has gone ahead with its plan to launch its iodine nasal spray despite the baffling results of a trial for the common cold last year.
The Melbourne-based pharma has announced it has launched Nasodine in the United States, the first market in which it is available. It's a nasal spray containing PVP-iodine, best known through the Betadine brand of throat gargle.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.